Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.21)
# 4,348
Out of 5,064 analysts
5
Total ratings
33.33%
Success rate
-32.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNTI Senti Biosciences | Initiates: Outperform | $6 | $1.94 | +209.28% | 1 | Nov 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $28.80 | +215.97% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $4.80 | +150.00% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $97.76 | +14.57% | 1 | Oct 28, 2022 |
Senti Biosciences
Nov 21, 2025
Initiates: Outperform
Price Target: $6
Current: $1.94
Upside: +209.28%
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $28.80
Upside: +215.97%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $4.80
Upside: +150.00%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $97.76
Upside: +14.57%